383 reports of this reaction
2.4% of all ACALABRUTINIB reports
#4 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #4 most commonly reported adverse reaction for ACALABRUTINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 383 FDA adverse event reports linking ACALABRUTINIB to PRODUCT DOSE OMISSION ISSUE. This represents approximately 2.4% of all 15,655 adverse event reports for this drug.
Patients taking ACALABRUTINIB who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is a less commonly reported adverse event for ACALABRUTINIB, but still significant enough to appear in the safety profile.
In addition to product dose omission issue, the following adverse reactions have been reported for ACALABRUTINIB:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 383 FDA reports for ACALABRUTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 2.4% of all adverse event reports for ACALABRUTINIB, making it a notable side effect.
If you experience product dose omission issue while taking ACALABRUTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.